Stocks like Advanced Micro Devices and CVS Health have managed to rebound sharply this year after suffering deep losses in 2024, and analysts think they still have room to rise. The artificial intelligence-driven rally has driven stock prices up significantly this year, with the S&P 500 on track to gain 17% year-to-date as of Tuesday morning. The Nasdaq Composite Index will rise 22% in 2025. Some of last year’s losers have made big comebacks. CNBC Pro screened data from FactSet to find the following S&P 500 stocks. It fell by at least 10% in 2024. Advanced Micro Devices was one of the companies on the list that rose more than 20% in 2025, but fell 18% in 2024. Stocks rebounded in 2025, rising nearly 80% year-over-year. Analysts’ average price target suggests the semiconductor stock could rise 33% from here. Earlier this month, TD Cowen named Advanced Micro Devices as one of his top candidates for 2026. “Despite the appropriate concerns, we believe spending on AI computing is durable, and AMD is solidifying its position as a winner,” wrote analyst Joshua Buchalter. “We believe this is an attractive entry point given the recent decline and excessive scrutiny of peers.” Buchalter’s $290 price target suggests the stock could appreciate 35% in the coming years. Pharmacy operator CVS Health also made the list. The stock price fell 43% in 2024, but it more than made up for it with a 77% rise this year. Analysts’ average price target suggests further upside of over 19%. In early December, JPMorgan highlighted CVS as one of its top choices for healthcare services. “Looking ahead to CVS Post-Investor Day and 2026, we remain positive with our outlook for adjusted EPS growth at a mid-teens CAGR through 2028, along with better/than-expected guidance for 2025/2026,” the bank wrote. “We were also encouraged to hear that CVS plans to normalize Caremark’s growth in 2027, highlight its progress in transitioning customers to an acquisition-based model, and see a healthy runway for growth with opportunities for management to outperform.” Analyst Lisa Gill’s price target of $101 is about 26% above Monday’s closing price for CVS stock. Conversely, analysts are more bearish on Albemarle. The chemical maker has rebounded 74% this year after posting a 40% loss in 2024. However, analysts’ average price estimate suggests a downside of more than 15%, meaning the company could lose some of its profits this year. However, analysts seem to be gradually becoming less bearish about the stock. Earlier this month, Morgan Stanley upgraded the stock to an equal weight rating, and UBS upgraded Albemarle to a buy rating. “The combination of rising demand for energy storage and a long-standing slowdown in capacity additions in the West now puts the lithium market in the red by 2026,” said UBS analyst Joshua Spector. “We expect lithium prices to rise throughout the year, which should be a positive factor for ALB stock.” Specter’s $185 price target is about 28% above Albemarle’s Monday closing price. His previous price estimate was $107, representing a 26% downside.
